An Open Label, Randomized Study to Evaluate Safety and Pharmacokinetics of Intravenous Infusion of Nanosomal Docetaxel Lipid Suspension for Injection in Patients With Advanced Solid Tumors

Trial Profile

An Open Label, Randomized Study to Evaluate Safety and Pharmacokinetics of Intravenous Infusion of Nanosomal Docetaxel Lipid Suspension for Injection in Patients With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Apr 2017

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Jina Pharmaceuticals
  • Most Recent Events

    • 08 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 07 Apr 2016 Planned End Date changed from 1 Nov 2016 to 1 Oct 2017 as reported by ClinicalTrials.gov record.
    • 07 Apr 2016 Planned primary completion date changed from 1 Nov 2015 to 1 Oct 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top